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A naplastic lymphoma kinase rearranged (ALK+) non–small-cell lung cancer demonstrates remarkable sen-
sitivity to crizotinib.1 Although other methods exist, the 
dominant method for determining ALK positivity uses the 
Abbott (Abbott Molecular, Des Plaines, IL) ALK break-
apart fluorescent in situ  hybridization (FISH) assay.2 The 
assay has clearly defined positivity criteria but borderline 
or atypical negative cases occur. Here we describe a case 
with an atypical negative FISH result that was later con-
firmed as ALK+ by both immunohistochemistry (IHC) and 
reverse transcription polymerase chain reaction (RT-PCR)
and responded well to crizotinib.
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FIGURE 1. A, CT scan of thorax 
before initiation of crizotinib. B, 
CT scan of thorax after 1 month 
therapy of crizotinib. CT, computed 
tomography.
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CASE PRESENTATION
A 44-year-old Chinese man with a 7 pack-year smoking 
history was referred to Shanghai Pulmonary Hospital in 
February 2013 for a left upper lobe lung mass with mul-
tiple bilateral intrapulmonary metastases, left pleural 
effusion, and 2R/4R/10L/11L lymphadenopathy. Pleural 
fluid cytology revealed adenocarcinoma and Scorpion 
Amplification Refractory Mutation system (AmoyDx Co., 
Xiamen, China). showed no detectable epidermal growth fac-
tor receptor mutation. He commenced chemotherapy with 
gemcitabine and cisplatin. However, after a single cycle, 
his symptoms worsened and imaging confirmed progressive 
FIGURE 2. A, Atypical negative ALK FISH result. Specimen hybridized with the Vysis break-apart ALK FISH assay showing mul-
tiple single 5'ALK signals (green arrows) with 3'-–5'ALK doublets (white arrows). B. Positive IHC result for ALK expression (40×). 
C, Reverse transcription polymerase chain reaction showing positive result for EML4-ALK transcript. ALK, Anaplastic lymphoma 
kinase; FISH, fluorescence in situ hybridization.
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disease. A second opinion was requested from the University 
of Colorado and a computed tomography–guided biopsy of 
the left upper lobe lesion was performed to permit additional 
molecular testing. In the interim, the patient commenced 
pemetrexed and nedaplatin. Unfortunately, after two cycles 
his shortness of breath worsened, with evidence of further 
progression on his scans (Fig. 1A).
Molecular testing on his repeat biopsy specimen 
revealed no mutations by SNaPshot multiplex PCR testing 
(Life Technologies, Carlsbad, CA). However, although tech-
nically negative, the ALK break-apart FISH test showed an 
atypical negative pattern. Specifically, 68% of cells demon-
strated single copies of the 5' ALK signal and numerous cells 
with doublets of the 5' ALK signal combined with one 3' ALK 
signal (Fig. 2A). Subsequently, confirmatory diagnostic assays 
demonstrated ALK protein expression by IHC using the D5F3 
antibody (Cell Signaling Technology Inc., Danvers, MA; H 
score = 150; Fig. 2B) and the presence of an echinoderm 
microtubule-associated protein-like 4 (EML4)-ALK transcript 
(E13;A20) by RT-PCR (Fig. 2C). The patient then received 
crizotinib (250 mg twice daily) as third-line therapy in May 
2013 with an impressive symptomatic improvement and CT 
response after 1 month of therapy (Fig. 1B). He remains on 
treatment with crizotinib with no evidence of progression as 
of September 2013.
DISCUSSION
Isolated 5' ALK signals have previously been reported, 
although, because the 5' probe is not located in the kinase 
region of ALK, these are usually considered ALK negative by 
FISH.3,4 Our patient showed multiple single copies of the 5' 
ALK signal plus additional 5' doublets combined with 3' sig-
nals, suggesting the possibility of a complex rearrangement. 
ALK positivity was confirmed by both IHC and RT-PCR and 
the patient responded well to crizotinib. A complex rearrange-
ment generating a different atypical negative FISH pattern (3' 
doublets fused with 5' signals) that also harbored a functional 
ALK fusion was recently described.5 When FISH is the initial 
diagnostic assay, consideration should be given to formally 
defining an atypical negative ALK FISH category for addi-
tional interrogation with alternative confirmatory assays.2
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